Study protocol for a randomised controlled feasibility trial of a virtual intervention (STRIDE) for symptom management, distress and adherence to adjuvant endocrine therapy after breast cancer

Jamie M Jacobs, Chelsea S Rapoport, Arielle Horenstein, Madison Clay, Emily A Walsh, Jeffrey Peppercorn, Jennifer S Temel, Joseph A Greer, Jamie M Jacobs, Chelsea S Rapoport, Arielle Horenstein, Madison Clay, Emily A Walsh, Jeffrey Peppercorn, Jennifer S Temel, Joseph A Greer

Abstract

Introduction: Patient adherence to adjuvant endocrine therapy (AET) after a diagnosis of hormone-sensitive breast cancer is poor. Previous interventions have failed to produce changes in adherence, address patient preferences or include theoretically informed and evidence-based components. Therefore, we iteratively developed a patient-centred, evidence-based, small-group, videoconference intervention to improve adherence and symptom management as well as reduce distress for patients taking AET after breast cancer (Symptom-Targeted Randomised Intervention for Distress and Adherence to Adjuvant Endocrine Therapy, STRIDE).

Methods and analysis: The current study is a non-blinded, randomised, controlled, feasibility trial of STRIDE compared with a medication monitoring control group. The primary objective is to examine the feasibility and acceptability of STRIDE, while secondary objectives are to assess changes in objective and subjective adherence, symptom distress and satisfaction with AET. Patients will be recruited from the Massachusetts General Hospital Cancer Center in Boston, Massachusetts. The total number of patients accrued will be 75, with ≥60 patients completing the study. All patients will store their AET in an electronic pill bottle for objective adherence monitoring. Patients randomly assigned to the STRIDE intervention will receive 6 weekly 1-hour sessions, in small groups of two, delivered via videoconferencing by a trained mental health professional. Patients assigned to the control group will store their medication in the electronic pill bottle and receive follow-up oncology care as usual. All participants will complete self-report psychosocial measures at baseline, 12 weeks and 24 weeks postbaseline.

Ethics and dissemination: The study is funded by the National Cancer Institute of the National Institutes of Health and is approved by the Dana-Farber/Harvard Cancer Center Institutional Review Board (Protocol #18-603, V.1.2, first approval date 1 February 2019). The study will be reported in accordance with the Consolidated Standards of Reporting Trials statement for non-pharmacological trials. Results will be published in peer-reviewed academic journals, presented at scientific meetings and disseminated to patient organisations and media outlets.Trial registration numberNCT03837496; Pre-results.

Keywords: Adult psychiatry; Breast tumours; MENTAL HEALTH; SOCIAL MEDICINE.

Conflict of interest statement

Competing interests: JJ is a paid consultant from Blue Note Therapeutics. JG receives royalties from Springer Humana Press, has research funding from Gaido Health/BCG Digital Ventures, and is a paid consultant from Concerto HealthAI and Blue Note Therapeutics. JP has received research funding from Pfizer, is a paid consultant for Athenex, and JP’s spouse is an employee of GlaxoSmithKline. All other authors declare that they have no conflicts of interest.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
CONSORT flow diagram. CONSORT, Consolidated Standards of Reporting Trials; MEMS, Medication Event Monitoring System; STRIDE, Symptom-Targeted Randomised Intervention for Distress and Adherence to Adjuvant Endocrine Therapy.

References

    1. Burstein HJ, Temin S, Anderson H, et al. . Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of clinical oncology clinical practice guideline focused update. J Clin Oncol 2014;32:2255–69. 10.1200/JCO.2013.54.2258
    1. , Davies C, Godwin J, et al. , Early Breast Cancer Trialists' Collaborative Group (EBCTCG) . Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378:771–84. 10.1016/S0140-6736(11)60993-8
    1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) . Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015;386:1341–52. 10.1016/S0140-6736(15)61074-1
    1. Chlebowski RT, Kim J, Haque R. Adherence to endocrine therapy in breast cancer adjuvant and prevention settings. Cancer Prev Res 2014;7:378–87. 10.1158/1940-6207.CAPR-13-0389
    1. Markkula A, Hietala M, Henningson M, et al. . Clinical profiles predict early nonadherence to adjuvant endocrine treatment in a prospective breast cancer cohort. Cancer Prev Res 2012;5:735–45. 10.1158/1940-6207.CAPR-11-0442
    1. Markkula A, Hietala M, Henningson M, et al. . Clinical profiles predict early nonadherence to adjuvant endocrine treatment in a prospective breast cancer cohort. Cancer Prev Res 2012;5:735–45. 10.1158/1940-6207.CAPR-11-0442
    1. Yood MU, Owusu C, Buist DSM, et al. . Mortality impact of less-than-standard therapy in older breast cancer patients. J Am Coll Surg 2008;206:66–75. 10.1016/j.jamcollsurg.2007.07.015
    1. DiMatteo MR, Giordani PJ, Lepper HS, et al. . Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002;40:794–811. 10.1097/00005650-200209000-00009
    1. Waterhouse DM, Calzone KA, Mele C, et al. . Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 1993;11:1189–97. 10.1200/JCO.1993.11.6.1189
    1. Makubate B, Donnan PT, Dewar JA, et al. . Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 2013;108:1515–24. 10.1038/bjc.2013.116
    1. Hadji P, Blettner M, Harbeck N, et al. . The patient's anastrozole compliance to therapy (PACT) program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol 2013;24:1505–12. 10.1093/annonc/mds653
    1. Czajkowski SM, Powell LH, Adler N, et al. . From ideas to efficacy: the orbit model for developing behavioral treatments for chronic diseases. Health Psychol 2015;34:971–82. 10.1037/hea0000161
    1. Yu K-D, Zhou Y, Liu G-Y, et al. . A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer. Breast Cancer Res Treat 2012;134:307–13. 10.1007/s10549-012-2059-8
    1. Davies C, Pan H, Godwin J, et al. . Long-Term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: atlas, a randomised trial. Lancet 2013;381:805–16. 10.1016/S0140-6736(12)61963-1
    1. Stanton AL, Petrie KJ, Partridge AH. Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry. Breast Cancer Res Treat 2014;145:525–34. 10.1007/s10549-014-2961-3
    1. Moon Z, Moss-Morris R, Hunter MS, et al. . Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review. Patient Prefer Adherence 2017;11:305–22. 10.2147/PPA.S126651
    1. Neven P, Markopoulos C, Tanner M, et al. . The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study. Breast 2014;23:393–9. 10.1016/j.breast.2014.02.009
    1. Greer JA, Amoyal N, Nisotel L, et al. . A systematic review of adherence to oral antineoplastic therapies. Oncologist 2016;21:354–76. 10.1634/theoncologist.2015-0405
    1. Onken LS, Carroll KM, Shoham V, et al. . Reenvisioning clinical science: unifying the discipline to improve the public health. Clin Psychol Sci 2014;2:22–34. 10.1177/2167702613497932
    1. Rounsaville BJ, Carroll KM, Onken LS. A stage model of behavioral therapies research: getting started and moving on from stage I. Clin Psychol: Sci Pract 2001;8:133–42. 10.1093/clipsy.8.2.133
    1. Jacobs JM, Walsh EA, Park ER, et al. . The patient's voice: adherence, symptoms, and distress related to adjuvant endocrine therapy after breast cancer. Int J Behav Med 2020;27:687–97. 10.1007/s12529-020-09908-2
    1. Antoni MH, Smith R. Stress Management Intervention for Women with Breast Cancer: Participant’s Workbook. Washington, DC: American Psychological Association, 2003.
    1. Safren SA, Hendriksen ES, Mayer KH, et al. . Cognitive-Behavioral therapy for HIV medication adherence and depression. Cogn Behav Pract 2004;11:415–24. 10.1016/S1077-7229(04)80058-0
    1. Dabrowski M, Boucher K, Ward JH, et al. . Clinical experience with the NCCN distress thermometer in breast cancer patients. J Natl Compr Canc Netw 2007;5:104–11. 10.6004/jnccn.2007.0011
    1. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 1999;21:1074–90. 10.1016/S0149-2918(99)80026-5
    1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361–70. 10.1111/j.1600-0447.1983.tb09716.x
    1. Harris PA, Taylor R, Thielke R, et al. . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81. 10.1016/j.jbi.2008.08.010
    1. Safren SA, Soroudi N, Gonzalez JS. Coping with chronic illness : a cognitive-behavioral therapy approach for adherence and depression workbook. New York: Oxford University Press, 2007.
    1. Wickersham K, Colbert A, Caruthers D, et al. . Assessing fidelity to an intervention in a randomized controlled trial to improve medication adherence. Nurs Res 2011;60:264–9. 10.1097/NNR.0b013e318221b6e6
    1. Pagoto SL, McDermott MM, Reed G, et al. . Can attention control conditions have detrimental effects on behavioral medicine randomized trials? Psychosom Med 2013;75:137–43. 10.1097/PSY.0b013e3182765dd2
    1. Attkisson CC, Zwick R. The client satisfaction questionnaire. psychometric properties and correlations with service utilization and psychotherapy outcome. Eval Program Plann 1982;5:233–7. 10.1016/0149-7189(82)90074-x
    1. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000;160:2101–7. 10.1001/archinte.160.14.2101
    1. Thivat E, Van Praagh I, Belliere A, et al. . Adherence with oral oncologic treatment in cancer patients: interest of an adherence score of all dosing errors. Oncology 2013;84:67–74. 10.1159/000342087
    1. Partridge AH, Archer L, Kornblith AB, et al. . Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol 2010;28:2418–22. 10.1200/JCO.2009.26.4671
    1. Horne R, Weinman J. Self-Regulation and self-management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health 2002;17:17–32. 10.1080/08870440290001502
    1. Cella D, Land SR, Chang C-H, et al. . Symptom measurement in the breast cancer prevention trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women. Breast Cancer Res Treat 2008;109:515–26. 10.1007/s10549-007-9682-9
    1. Abetz L, Coombs JH, Keininger DL, et al. . Development of the cancer therapy satisfaction questionnaire: item generation and content validity testing. Value Health 2005;8 Suppl 1:S41–53. 10.1111/j.1524-4733.2005.00073.x
    1. Brady MJ, Cella DF, Mo F, et al. . Reliability and validity of the functional assessment of cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 1997;15:974–86. 10.1200/JCO.1997.15.3.974
    1. Risser J, Jacobson TA, Kripalani S. Development and psychometric evaluation of the self-efficacy for appropriate medication use scale (SEAMS) in low-literacy patients with chronic disease. J Nurs Meas 2007;15:203–19. 10.1891/106137407783095757
    1. Brett J, Hulbert-Williams NJ, Fenlon D, et al. . Psychometric properties of the beliefs about medicine Questionnaire-adjuvant endocrine therapy (BMQ-AET) for women taking AETs following early-stage breast cancer. Health Psychol Open 2017;4:205510291774046. 10.1177/2055102917740469
    1. Zimet GD, Dahlem NW, Zimet SG, et al. . The multidimensional scale of perceived social support. J Pers Assess 1988;52:30–41. 10.1207/s15327752jpa5201_2
    1. Antoni MH, Lechner SC, Kazi A, et al. . How stress management improves quality of life after treatment for breast cancer. J Consult Clin Psychol 2006;74:1143–52. 10.1037/0022-006X.74.6.1143
    1. Shelby RA, Edmond SN, Wren AA, et al. . Self-Efficacy for coping with symptoms moderates the relationship between physical symptoms and well-being in breast cancer survivors taking adjuvant endocrine therapy. Support Care Cancer 2014;22:2851–9. 10.1007/s00520-014-2269-1
    1. Lai J-S, Wagner LI, Jacobsen PB, et al. . Self-Reported cognitive concerns and abilities: two sides of one coin? Psychooncology 2014;23:1133–41. 10.1002/pon.3522
    1. Little RJ, D'Agostino R, Cohen ML, et al. . The prevention and treatment of missing data in clinical trials. N Engl J Med 2012;367:1355–60. 10.1056/NEJMsr1203730
    1. Cohen J. A power primer. Psychol Bull 1992;112:155–9. 10.1037/0033-2909.112.1.155
    1. Kraemer HC, Mintz J, Noda A, et al. . Caution regarding the use of pilot studies to guide power calculations for study proposals. Arch Gen Psychiatry 2006;63:484–9. 10.1001/archpsyc.63.5.484

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere